2590-0188

Immuno-Oncology Technology

Elsevier

View prefix report (10.1016)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1233 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1233 DOIs
2

Attach ORCID iDs across 1184 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact1184 DOIs
3

Deposit reference lists for 1122 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact1122 DOIs

DOIs for this ISSN

Showing the top 5 of 1233 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 CD47–SIRPα-targeted therapeutics: status and prospects (10.1016/j.iotech.2022.100070)
Abstract ORCID
106.68 135
2 LBA4 Preliminary safety and efficacy of adagrasib with pembr… (10.1016/j.iotech.2022.100360)
Abstract References ORCID
106.12 25
3 Clinical landscape of LAG-3-targeted therapy (10.1016/j.iotech.2022.100079)
Abstract ORCID
95.95 82
4 65O CheckMate 73L: Phase III study comparing nivolumab (N) +… (10.1016/j.iotech.2024.100808)
Abstract References ORCID
95.91 18
5 A user's perspective on GeoMxTM digital spatial profiling (10.1016/j.iotech.2019.05.001)
Abstract ORCID
91.94 68
6 1O IMpower010: ctDNA status in patients (pts) with resected… (10.1016/j.iotech.2022.100106)
Abstract References ORCID
90.31 15
7 155P BNT113 + pembrolizumab as first-line treatment in patie… (10.1016/j.iotech.2022.100267)
Abstract References ORCID
88.21 14
8 Nanobodies as non-invasive imaging tools (10.1016/j.iotech.2020.07.001)
Abstract ORCID
85.80 51
9 117O Stereotactic body radiotherapy (SBRT) with pembrolizuma… (10.1016/j.iotech.2024.100746)
Abstract References ORCID
83.55 12
10 Non-viral chimeric antigen receptor (CAR) T cells going vira… (10.1016/j.iotech.2023.100375)
Abstract ORCID
82.17 43
11 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembr… (10.1016/j.iotech.2023.100593)
Abstract References ORCID
80.94 11
12 Computational cancer neoantigen prediction: current status a… (10.1016/j.iotech.2021.100052)
Abstract ORCID
80.64 40
13 Function and evolution of the prototypic CD28ζ and 4-1BBζ ch… (10.1016/j.iotech.2020.09.001)
Abstract ORCID
75.26 31
14 65O Phase III LEAP-008 study of lenvatinib plus pembrolizuma… (10.1016/j.iotech.2023.100537)
Abstract References ORCID
75.00 9
15 119O Long-term efficacy and patterns of response of lifileuc… (10.1016/j.iotech.2023.100591)
Abstract References ORCID
75.00 9
16 120MO Adjuvant pembrolizumab versus placebo for early-stage… (10.1016/j.iotech.2023.100592)
Abstract References ORCID
75.00 9
17 T-cell-receptor cross-recognition and strategies to select s… (10.1016/j.iotech.2019.06.003)
Abstract ORCID
73.86 29
18 MART-1 TCR gene-modified peripheral blood T cells for the tr… (10.1016/j.iotech.2022.100089)
Abstract ORCID
72.36 27
19 ATMP development and pre-GMP environment in academia: a safe… (10.1016/j.iotech.2022.100099)
Abstract ORCID
70.75 25
20 Microbiome-based interventions: therapeutic strategies in ca… (10.1016/j.iotech.2020.11.001)
Abstract ORCID
68.09 22
21 59MO Final analysis of AK105-302: A randomized, double-blind… (10.1016/j.iotech.2022.100164)
Abstract References ORCID
67.73 7
22 LBA5 A phase II study of neoadjuvant SHR-1701 with or withou… (10.1016/j.iotech.2022.100361)
Abstract References ORCID
67.73 7
23 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in im… (10.1016/j.iotech.2024.100747)
Abstract References ORCID
67.73 7
24 LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus… (10.1016/j.iotech.2024.101025)
Abstract References ORCID
67.73 7
25 LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant c… (10.1016/j.iotech.2024.101027)
Abstract References ORCID
67.73 7
26 1,2,3, MHC: a review of mass-spectrometry-based immunopeptid… (10.1016/j.iotech.2021.100042)
Abstract ORCID
65.05 19
27 TCR sequencing: applications in immuno-oncology research (10.1016/j.iotech.2023.100373)
Abstract ORCID
65.05 19
28 Molecular imaging for cancer immunotherapy (10.1016/j.iotech.2020.03.001)
Abstract ORCID
63.94 18
29 Characterization and translational development of IOA-289, a… (10.1016/j.iotech.2023.100384)
Abstract ORCID
63.94 18
30 35MO Number of IL-2 doses and clinical outcomes of tumor-inf… (10.1016/j.iotech.2022.100140)
Abstract References ORCID
63.38 6
31 46P Development of an allogeneic CAR-T targeting MUC1-C (MUC… (10.1016/j.iotech.2022.100151)
Abstract References ORCID
63.38 6
32 85P Tislelizumab combined with apatinib and oxaliplatin plus… (10.1016/j.iotech.2022.100189)
Abstract References ORCID
63.38 6
33 Generation of chimeric antigen receptor macrophages from hum… (10.1016/j.iotech.2023.100409)
Abstract ORCID
62.76 17
34 Intervention strategies for microbial therapeutics in cancer… (10.1016/j.iotech.2020.05.001)
Abstract ORCID
61.52 16
35 Multimodal predictors for precision immunotherapy (10.1016/j.iotech.2022.100071)
Abstract ORCID
60.21 15
36 Basics of advanced therapy medicinal product development in… (10.1016/j.iotech.2023.100411)
Abstract ORCID
60.21 15
37 Updates in the pathogenesis and management of immune-related… (10.1016/j.iotech.2024.100704)
Abstract ORCID
60.21 15
38 Immune checkpoints in thymic epithelial tumors: challenges a… (10.1016/j.iotech.2019.09.002)
Abstract ORCID
58.80 14
39 Intratumoural immunotherapy: activation of nucleic acid sens… (10.1016/j.iotech.2019.10.001)
Abstract ORCID
58.80 14
40 8P Phenotypic characterization of infused tumor-infiltrating… (10.1016/j.iotech.2022.100113)
Abstract References ORCID
58.36 5
41 132P Randomized phase III study of tislelizumab plus chemoth… (10.1016/j.iotech.2022.100244)
Abstract References ORCID
58.36 5
42 174P First-in-human study of NGM707, an ILT2/ILT4 dual antag… (10.1016/j.iotech.2022.100286)
Abstract References ORCID
58.36 5
43 201P Phase II study of taminadenant (A2AR antagonist) + spar… (10.1016/j.iotech.2022.100312)
Abstract References ORCID
58.36 5
44 132P A phase I clinical trial of QLS31905 in advanced solid… (10.1016/j.iotech.2023.100604)
Abstract References ORCID
58.36 5
45 121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (… (10.1016/j.iotech.2024.100750)
Abstract References ORCID
58.36 5
46 Autoantibodies involved in primary and secondary adrenal ins… (10.1016/j.iotech.2023.100374)
Abstract ORCID
57.31 13
47 High multiplex analysis of the immune microenvironment in bo… (10.1016/j.iotech.2020.02.001)
Abstract ORCID
55.70 12
48 Cell Squeeze: driving more effective CD8 T-cell activation t… (10.1016/j.iotech.2022.100091)
Abstract ORCID
53.96 11
49 6P Response and survival according to the interferon-gamma (… (10.1016/j.iotech.2022.100111)
Abstract References ORCID
52.42 4
50 66P Real-world data of first-line chemo-immunotherapy for pa… (10.1016/j.iotech.2022.100171)
Abstract References ORCID
52.42 4